Menu
Contact Us
Subscribe
Menu

ML&P Blog: Our insight into current issues

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and innovation policy as they impact on access to medicines. These posts are listed below. We also have a newsletter for those interested in being notified when new articles are posted.

Latest Blog Posts

World Health Assembly adopts the Pandemic Agreement

Kaitlin Mara -
"I see no objection, the resolution is adopted," said Teodoro J. Herbosa, Secretary of Health of the Philippines and President of the 78th World...

The People vs. AbbVie

Ellen 't Hoen -
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

The Pandemic Agreement is here

Ellen 't Hoen -
In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...

Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development

Christopher Garrison -
This is an excerpt from a longer report on AI, medicines development and the patent system. Download the full report here (or by clicking...

Expanding local production is essential for pandemic preparedness. It requires, however, transfer of technology.

Ellen 't Hoen -
Madam co-chairs, delegates,  This very week, from 7 to 9 April the 3rd World Local Production Forum is taking place in Abu Dhabi. Actions towards...

Respect for intellectual property law includes respecting the flexibilities it contains to protect the public interest: ML&P’s opening statement to the INB

Kaitlin Mara -
Thank you for the opportunity to speak. And for the latest draft of the pandemic agreementshared with us on 26 March. In particular, we...

Will Europe block the Pandemic Agreement because of one word?

Guilherme Ferrari Faviero and Ellen 't Hoen -
This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...

“Mutually agreed terms and conditions,” says it all.

Ellen 't Hoen -
On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...

“This week, the medicines were not there”: What is at stake in the pandemic agreement

Ellen 't Hoen -
Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...

A better way to solve a crisis: A new mechanism for incentivising R&D on new antimicrobials

Kaitlin Mara -
Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...

Newsletter

Never miss a post! Sign up for ML&P's newsletter.

Posts by topic

Year-End Wrap-Ups

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Medicines Law & Policy -
Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Ellen 't Hoen -
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Wrapping up 2022 with some noteworthy medicines, law and policy events

Medicines Law & Policy -
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy. Also in 2022, Covid-19 remained a central...

Wrapping up 2021 – some noteworthy medicines law and policy events

Ellen 't Hoen -
Welcome to the annual end of the year blog, our highly biased overview of noteworthy events in the field of medicines law and policy....
Load more

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's newsletter.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.